Abstract
Due to their high prevalence, non-alcoholic fatty liver disease (NAFLD), insulin resistance (IR) and hepatitis C virus (HCV) infection are bound to cohabit. However, the relationship between these 3 entities is complex and multilayered. HCV, particularly genotype 3, may induce a “viral” steatosis, morphologically indistinguishable from the steatosis of NAFLD but with different implications and prognosis. On the other hand, epidemiological and experimental data show that patients with HCV have a higher risk of developing IR and, in susceptible individuals, type 2 diabetes (T2D). In patients with HCV, T2D increases fibrosis progression rate, increases the incidence of HCC, worsens liver-related outcomes and worsens response to interferon-α based therapy. We conclude by discussing a possible increased incidence of cardiovascular events in HCV patients.
Keywords: Fibrosis, hepatitis C virus, non-alcoholic fatty liver disease, steatosis.
Reviews on Recent Clinical Trials
Title:Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection
Volume: 9 Issue: 3
Author(s): Nicolas Goossens and Francesco Negro
Affiliation:
Keywords: Fibrosis, hepatitis C virus, non-alcoholic fatty liver disease, steatosis.
Abstract: Due to their high prevalence, non-alcoholic fatty liver disease (NAFLD), insulin resistance (IR) and hepatitis C virus (HCV) infection are bound to cohabit. However, the relationship between these 3 entities is complex and multilayered. HCV, particularly genotype 3, may induce a “viral” steatosis, morphologically indistinguishable from the steatosis of NAFLD but with different implications and prognosis. On the other hand, epidemiological and experimental data show that patients with HCV have a higher risk of developing IR and, in susceptible individuals, type 2 diabetes (T2D). In patients with HCV, T2D increases fibrosis progression rate, increases the incidence of HCC, worsens liver-related outcomes and worsens response to interferon-α based therapy. We conclude by discussing a possible increased incidence of cardiovascular events in HCV patients.
Export Options
About this article
Cite this article as:
Goossens Nicolas and Negro Francesco, Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection, Reviews on Recent Clinical Trials 2014; 9 (3) . https://dx.doi.org/10.2174/1574887109666141216101939
DOI https://dx.doi.org/10.2174/1574887109666141216101939 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthetic and Medicinal Prospective of Structurally Modified Curcumins
Current Topics in Medicinal Chemistry Predictive Factors of follow-up Non-attendance and Mortality Among Adults with Type 2 Diabetes Mellitus- an Analysis of the Malaysian Diabetes Registry 2009
Current Diabetes Reviews Immediate and Late Adverse Reactions to Iodinated Contrast Media: A Pharmacological Point of View
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Time Dependent Distribution of MicroRNA 144 after Intravenous Delivery
MicroRNA Familial Mediterranean Fever
Current Rheumatology Reviews Dietary Patterns and Prevention of Type 2 Diabetes: From Research to Clinical Practice; A Systematic Review
Current Diabetes Reviews Therapies in Development for Non-Infectious Uveitis
Current Molecular Medicine Beta-cell Management in Type 2 Diabetes: Beneficial Role of Nutraceuticals
Endocrine, Metabolic & Immune Disorders - Drug Targets Cannabidiol as a Putative Novel Therapy for Diabetic Retinopathy: A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development
Current Pharmacogenomics and Personalized Medicine Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer
Current Medicinal Chemistry How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?
Current Pharmaceutical Design Medicinal Agents and Metabolic Syndrome
Current Medicinal Chemistry Effect of Simvastatin on Inflammatory Cytokines Balance in Air Pouch Granuloma Model
Inflammation & Allergy - Drug Targets (Discontinued) Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Editorial (Should Chronic Kidney Disease be Considered as a Coronary Heart Disease Equivalent?)
Current Vascular Pharmacology Recent Developments in Patents Targeting Toll-Like Receptor Genes
Recent Patents on DNA & Gene Sequences From Molecular Footprints of Disease to New Therapeutic Interventions in Diabetic Nephropathy: A Detective Story
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Bone Disease in Diabetes
Current Diabetes Reviews Retracted: Tocotrienols and its Role in Cardiovascular Health- a Lead for Drug Design
Current Pharmaceutical Design